The Middle East Tapentadol market, by Therapeutic Application (Pain Management (Neuropathic Pain, Cancer Pain, and Others), and Cough Treatment), and by Countries (KSA, UAE, Bahrain, Oman, Qatar, Israel, Iran) was valued at US$ 0.86 million in 2016 and is projected to exhibit a CAGR of 6.1% over the forecast period (2017–2025), as highlighted in a new report published by Coherent Market Insights. Rising prevalence of pain-associated diseases such as cancer and diabetic neuropathy and unavailability of effective alternate therapy for management of neuropathic pain are expected to be the major factors driving growth of the Middle East tapentadol market over the forecast period.
Janssen Pharmaceutical sold its license of marketing and distribution of the U.S. to Depomed, Inc. and in April 2017, Depomed, Inc. won the patent for tapentadol. Three ongoing clinical trials for tapentadol are being carried on for various indications and age groups. Positive results from these trials is expected to cause the tapentadol market to gain rapid traction. Currently, tapentadol is only approved for consumption by adults and is not recommended for children due to its high therapeutic efficacy. However, one in three clinical trials are subjected to pediatric use. Grünenthal GmbH is carrying out an open-label trial, enrolling subjects aged 6 years to 18 years, which is estimated to be completed in December 2018. Another trial by St. Olavs Hospital is for pre- and post-operative pain relief after primary knee arthroplasty with estimated study completion year 2021.
Browse 10 Market Data Tables And 11 Figures Spread Through 106 Pages and In-depth TOC on Middle East Tapentadol Market, By Therapeutic Application (Pain Management (Neuropathic Pain, Cancer Pain, And Others), And Cough Treatment), and By Countries (KSA, UAE, Bahrain, Oman, Qatar, Israel, Iran) - Forecast To 2025
To know the latest trends and insights prevalent in the Middle East tapentadol market, click the link below:
Tapentadol can be used for various other applications, as it is also found to be the safest and best first-line treatment choice for advanced chronic kidney disease. However, clinical trials are still required for it to be prescribed for the same. Furthermore, pilot studies have been performed on patients suffering from moderate-to-severe chronic back pain, published in the National Center for Biotechnology Information.
Increasing off-label applications for this moderately addictive drug along with low competition for existing indications, and robust pipeline is expected to boost growth of the tapentadol market over the forecast period.
Key Takeaways of the Middle East Tapentadol Market:
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Coherent Market Insights
1001 4th Ave,
Seattle, WA 98154
Email: [email protected]
Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154
Talk to our research consultant to design an exclusive report as per your research needs.
We aim to fulfil client's research demands with tailored research solutions.
We aim to provide research studies in quickest turnaround time and in a much cost effective manner.
We cover each industry from supply and demand side with an aim to provide a most holistic research study.
We strive to provide most accurate and reliable research findings in our research reports.